Use of the CogState Brief Battery in the assessment of Alzheimer's disease related cognitive impairment in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study
Yen Ying Lim, Kathryn A Ellis, Karra Harrington, David Ames, Ralph N Martins, Colin L Masters, Christopher Rowe, Greg Savage, Cassandra Szoeke, David Darby, Paul Maruff
Journal of Clinical and Experimental Neuropsychology | TAYLOR & FRANCIS INC | Published : 2012
David Darby and Paul Maruff are full time employees of CogState Ltd, the company that provided the CogState Brief Battery. Funding for the study was provided in part by the study partners: Australian Commonwealth Scientific Industrial and research Organization (CSIRO), Edith Cowan University (ECU), Mental Health Research institute (MHRI), Alzheimer's Australia (AA), National Ageing Research Institute (NARI), Austin Health, CogState Ltd., Hollywood Private Hospital, and Sir Charles Gardner Hospital. The Australian Imaging, Biomarkers and Lifestyle (AIBL) investigators thank Richard Head of CSIRO for initiating and facilitating the AIBL collaboration. The study also received support from the National Health and Medical Research Council (NHMRC) and the Dementia Collaborative Research Centres program (DCRC2). Cassandra Szoeke has been partially supported by research fellowships funded by Alzheimer's Australia and the NHMRC. Alzheimer's Australia (Victoria and Western Australia) assisted with promotion of the study and the screening of telephone calls from volunteers. The AIBL team wishes to thank the clinicians who referred patients with Alzheimer's disease to the study: Brian Chambers, Edmond Chiu, Roger Clarnette, David Darby, Mary Davison, John Drago, Peter Drysdale, Jacqueline Gilbert, Kwang Lim, Nicola Lautenschlager, Dina LoGiudice, Peter McCardle, Steve McFarlane, Alastair Mander, John Merory, Daniel O'Connor, Ron Scholes, Mathew Samuel, Darshan Trivedi, and Michael Woodward. We thank all those who participated in the study for their commitment and dedication to helping advance research into the early detection and causation of AD.